Drugs / Nurandociguat
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 19 trials | ||||||
| Phase 1 | NCT07431294 | Jan → May 2027 expected | coronary artery disorder | Bayer | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07722585 | Jul → Oct 2026 expected | chronic kidney disease | Bayer | Recruiting | No outcome recorded |
| Phase 1 | NCT07515339 | Apr → Jun 2026 | chronic kidney disease | Bayer | Withdrawn | No outcome recorded |
| Phase 1 | NCT06428825 | Aug 2024 → Nov 2025 | chronic kidney disease, hypertensive disorder | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT06487845 | Jul → Sep 2024 | chronic kidney disease, diabetic retinopathy | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT06402721 | May 2024 → Feb 2025 | chronic kidney disease | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT05800444 | Apr → Jul 2023 | chronic kidney disease | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT05491642 | Sep 2022 → Jan 2023 | chronic kidney disease, hypertensive disorder | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT05515432 | Aug 2022 → Mar 2023 | chronic kidney disease, impaired renal function disease | Bayer | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06522997 | Aug 2024 → Oct 2025 | chronic kidney disease | Bayer | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-08-22 | Bayer | Bayer initiates Phase II study of soluble guanylate cyclase activator (BAY3283142) in patients with chronic kidney disease bayer.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nurandociguat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07515339 ↗ |
| Known as | BAY3283142 | “The study treatment nurandociguat (also called BAY 3283142) is a new medicine being developed to help people with CKD.” NCT07515339 ↗8“Nurandociguat (BAY3283142) old tablet - SD” NCT07722585 ↗ |
| Action | Activate | “It activates a protein called soluble guanylate cyclase (sGC)” NCT05491642 ↗ |
| Modality | Small molecule | — CHEMBL6068024 ↗ |
| Route | Oral | “Oral administration” NCT05491642 ↗ |